Please ensure Javascript is enabled for purposes of website accessibility

Why Evofem Biosciences Stock Is Falling Today

By Prosper Junior Bakiny - Updated Mar 5, 2021 at 1:05PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The company's performance during the fourth quarter was short of expectations.

What happened

After the close of Thursday's trading session, Evofem Biosciences (EVFM 6.80%) released its financial results for the fourth quarter and full year ending Dec. 31. Investors did not like what they saw, and the biopharmaceutical company's stock is dropping sharply on Friday as a result. As of 12:28 p.m. EST, Evofem Biosciences' shares were down by 35.6%.

So what

For the fourth quarter of its fiscal year 2020, net sales were $168,000, a significant improvement over the year-ago period, during which it did not report a single dollar in sales.

Still, the company's top line fell short of the $1.7 million consensus analyst estimate. On the bottom line, Evofem Biosciences reported a net loss of $40.6 million, or $0.50 per share, compared to a net loss of $12.7 million ($0.27 per share) it recorded during the prior-year quarter.

The company's bottom line also fell well short of the $0.36 net loss per share analysts on average were expecting. Missing estimates on both the top and bottom lines is never ideal, and it explains why shares of the healthcare company are falling off a cliff today.

Downward-bound graph on a blackboard.

Image source: Getty Images.

Now what

Unfortunately, there is more bad news for investors. Evofem Biosciences filed for a $150 million mixed-shelf offering. A shelf offering allows a company to issue securities periodically, as opposed to all at once. In a mixed-shelf offering, the company in question can issue a mix of securities, including common stock, warrants, and debt securities. These transactions can lead to share dilution over time. Evofem Biosciences' announced mixed shelf offering is probably contributing to its underperformance in the market today. 

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Evofem Biosciences, Inc. Stock Quote
Evofem Biosciences, Inc.
$1.10 (6.80%) $0.07

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/20/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.